Semaglutide Tied to 50% Lower Risk for Epilepsy in Diabetes, New Study Finds

December 11, 2025

ATLANTA — The popular diabetes and weight-loss drug semaglutide may offer a significant neurological benefit beyond blood sugar control: a drastically reduced risk of developing epilepsy.

According to new research presented this week at the American Epilepsy Society (AES) 2025 Annual Meeting, patients with type 2 diabetes who took semaglutide had a 50% lower risk of being diagnosed with epilepsy compared to those on other diabetes medications. The findings suggest that the drug’s protective effects may stem from neuroprotective mechanisms unrelated to its well-known ability to lower hemoglobin A1c or body weight.

The study, which analyzed data from thousands of patients, offers a promising new avenue for managing the increased seizure risk known to accompany type 2 diabetes.

A Surprising Neurological Benefit

Type 2 diabetes is a known risk factor for epilepsy, with patients facing significantly higher odds of developing seizures due to vascular damage, chronic inflammation, and metabolic disturbances in the brain. However, until now, it was unclear if glucose-lowering medications could mitigate this specific risk.

Researchers led by Dr. Edy Kornelius of Chung Shan Medical University evaluated real-world data to compare the incidence of epilepsy among patients prescribed semaglutide versus those prescribed other standard diabetes treatments, such as DPP-4 inhibitors.

The results were striking. Patients on semaglutide demonstrated a 50% reduction in the risk of new-onset epilepsy. Crucially, statistical analysis revealed that this benefit was consistent regardless of how much weight the patients lost or how significantly their blood sugar levels improved.

“This protective signal appears to be driven by pathways distinct from the metabolic improvements we typically track,” said the researchers during the presentation. “This points to a direct neuroprotective effect of GLP-1 receptor activation.”

Beyond Blood Sugar: The Mechanism

The study adds to a growing body of evidence that GLP-1 receptor agonists—the class of drugs to which semaglutide belongs—exert powerful anti-inflammatory effects in the brain.

Preclinical models cited alongside the clinical findings suggest that semaglutide may block the NLRP3 inflammasome, a protein complex that triggers inflammation. In the context of the brain, chronic inflammation is a key driver of neuronal hyperexcitability, which can lead to seizures. By inhibiting this pathway, semaglutide may prevent the “kindling” process that turns a healthy brain into an epileptic one.

“We are seeing a potential dual benefit where a drug manages the systemic metabolic disease while simultaneously protecting the central nervous system,” explained Dr. Sarah Vane, a neurologist and researcher who was not involved in the study. “If these findings hold up in prospective trials, it could change how we choose medications for diabetic patients who have a history of head injury or stroke, which already predispose them to epilepsy.”

Implications for Public Health

The findings come at a time when semaglutide (marketed as Ozempic for diabetes and Wegovy for weight loss) is already one of the most prescribed medications globally.

For the millions of people living with type 2 diabetes, the risk of developing late-onset epilepsy is a serious but often overlooked complication. Seizures in older adults can be subtle, often mistaken for confusion or dementia, yet they carry a high risk of falls, injury, and mortality.

“If a patient has type 2 diabetes and additional risk factors for seizures—such as a prior stroke or family history—this data suggests that choosing a GLP-1 receptor agonist like semaglutide might be a superior clinical decision compared to other classes of drugs,” said Dr. Vane.

Limitations and Future Research

While the 50% risk reduction is statistically significant, experts caution that the study is observational. This means it looks back at existing patient data rather than assigning patients to a treatment in a controlled experiment.

“Retrospective studies are excellent for generating hypotheses, but they cannot definitively prove cause and effect,” noted Dr. Kornelius. “We need randomized controlled trials designed specifically to measure seizure outcomes to confirm this benefit.”

Additionally, the study focused on semaglutide. It remains to be seen if other drugs in the same class, such as tirzepatide or liraglutide, offer the same degree of protection, though early meta-analyses suggest the benefit may be a “class effect” of GLP-1 agonists.

Key Takeaways for Patients

• Diabetes and Epilepsy Link: People with type 2 diabetes have a higher baseline risk of developing epilepsy than the general population.

• The Findings: Use of semaglutide was associated with a roughly 50% lower risk of developing epilepsy compared to other treatments.

• The “Why”: The benefit appears to be neuroprotective and anti-inflammatory, rather than just a result of lowering blood sugar.

• Consult Your Doctor: Patients should not stop or switch medications without medical supervision. These findings add another layer to the conversation between patients and providers when selecting diabetes therapy.

References

1. Primary Study Presentation: Kornelius, E., et al. “Semaglutide Tied to 50% Lower Risk for Epilepsy in Diabetes.” Presented at the American Epilepsy Society (AES) 2025 Annual Meeting, December 2025.

2. Supporting Meta-Analysis: Sindhu, U., et al. (2024). “Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: A meta-analysis.” Epilepsia Open, 9(6): 2528-2536. DOI: 10.1002/epi4.13091.